Trial 13NHL-23-3


A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Chemotherapy: Local
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Ann Mohrbacher, M.D.
Other Trial Staff:  Christine Duran, Coordinator, Mary Ordaz, D.M., Niranjan Bhatt, D.M., Donna Fernando, Coordinator, Nelli Dimitrova, D.M., Hannah Trey, Coordinator, Sonny Tong, D.M., Jenny Kim, D.M., Aliya Anvery, Coordinator, Rhiannon Imbeah, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.